Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 29.41 USD -0.37% Market Closed
Market Cap: 4.9B USD

During the last 3 months Alkermes Plc insiders have not bought any shares, and sold 786.9k USD worth of shares. The stock price has increased by 6% over this period (open performance analysis).

The last transaction was made on Dec 3, 2025 by Hopkinson Craig C. , who sold 112.4k USD worth of ALKS shares.

Last Transactions:
Hopkinson Craig C.
$-112.4k
Hopkinson Craig C.
$-117.2k
Hopkinson Craig C.
$-273.4k
Hopkinson Craig C.
$-283.8k
Nichols Christian Todd
$-103.7k
Nichols Christian Todd
$-106.5k
Parisi Samuel Joseph
$-65.9k
Parisi Samuel Joseph
$-132k
Parisi Samuel Joseph
$-47.4k
Hopkinson Craig C.
$-1.2m
Hopkinson Craig C.
$-5.6m
Hopkinson Craig C.
$-3.2m
Hopkinson Craig C.
$-2m
Laurencin Cato T
$-85.7k
Hopkinson Craig C.
$-290.5k
Hopkinson Craig C.
$-441.6k
Nichols Christian Todd
$-151.8k
Hopkinson Craig C.
$-1.8m
Hopkinson Craig C.
$-309.2k
Nichols Christian Todd
$-292.7k
Parisi Samuel Joseph
$-75.9k
Laurencin Cato T
$-85.7k
Laurencin Cato T
$-84k
Laurencin Cato T
$-88.2k
Nichols Christian Todd
$-784.9k
Wysenski Nancy
$-1.3m
Daglio David Angelo Jr.
$+815.7k
Nichols Christian Todd
$-211.2k
Landine Michael J
$-1.5m
Landine Michael J
$-680.4k
Pops Richard F
$-2.6m
Pops Richard F
$-6.2m
View All Transactions

During the last 3 months Alkermes Plc insiders have not bought any shares, and sold 786.9k USD worth of shares. The stock price has increased by 6% over this period (open performance analysis).

The last transaction was made on Dec 3, 2025 by Hopkinson Craig C. , who sold 112.4k USD worth of ALKS shares.

Sold
0-3
months
786.9k USD
1
3-6
months
103.7k USD
1
6-9
months
106.5k USD
1
9-12
months
10.3m USD
2
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD

Alkermes Plc
Insider Trading Chart

Alkermes Plc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Alkermes Plc
Last Insider Transactions

Global
Insiders Monitor

Alkermes Plc
Glance View

Alkermes Plc, an Irish biopharmaceutical company, has carved its niche at the intersection of neuroscience and oncology, a strategic pivot that underscores its commitment to addressing unmet medical needs. The firm's focus lies in the development of innovative pharmaceuticals that offer hope and efficacy where other treatments may fall short. These include proprietary products as well as collaborations with more established pharmaceutical entities. At the heart of Alkermes' operations is its R&D engine, which drives the development of cutting-edge treatments leveraging the company's proprietary technology platforms. This not only underpins its internal drug development pipeline but also enhances its value proposition in collaborations with partner companies, fostering a symbiotic environment where innovation and mutual benefit intersect. The way Alkermes generates revenue is multifaceted, reflecting its dynamic business model. The company earns through product sales from its proprietary medicines, which are tailored for chronic diseases such as schizophrenia, addiction, and multiple sclerosis. Moreover, a significant portion of its income is derived from strategic collaborations and royalty agreements, where it grants larger pharmaceutical companies access to its technology platforms or the commercial rights to certain drug formulations. These alliances often entail milestone-based payments and ongoing royalties contingent upon sales performance, providing Alkermes with a steady revenue stream and reducing its dependency on the success of any single product. By balancing its own product development with these partnerships, Alkermes secures financial robustness while maintaining its position at the forefront of pharmaceutical innovation.

ALKS Intrinsic Value
30.57 USD
Undervaluation 4%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top